Demographic and descriptive data for Cohort 2 and patients with unchanged disease activity and medication included for test-retest reliability.
| Characteristics | Cohort 2, Median (Q1–Q3), n = 64 | Patients Performing Test-retest, Median (Q1–Q3), n = 37 |
|---|---|---|
| Diagnosis, PM/DM/definite JDM, n | 29/34/1 | 16/20/1 |
| Definite PM/probable PM, n | 19/10 | |
| Definite DM/probable DM, n | 29/5 | |
| Sex, women/men, n | 46/18 | 29/8 |
| Age, yrs | 55.0 (44.0–64.0) | 56.0 (46.0–65.0) |
| Diagnosis duration, mo | 42.0 (13.0–78.0) | 60 (24.0–120.0) |
| Prednisone dose, mg/day | 7.5 (0.0–15.0) | 5.0 (0.5–10.0) |
| Physician’s global assessment of disease activity, VAS, 0–10 | 1.9 (0.7–3.8) | 1.5 (0.7–3.3) |
| Physician’s assessment of extramuscular disease activity, VAS, 0–10 | 1.7 (0.5–3.3) | 1.2 (0.4–2.9) |
| Serum CPK, l/U | 134 (73–466) | 120 (88–228) |
| MYOACT, total score, 0–1 | 0.05 (0.01–0.12) | 0.03 (0.01–0.08) |
| MITAX, total score, 0–1 | 0.06 (0.03–0.16) | 0.06 (0.03–0.10) |
| MMT 8, 0–80 | 72 (66–78) | 73 (69–78) |
| FI-2, shoulder flexion, 0–60 | 27.0 (15.0–60.0) | 32.0 (17.0–60.0) |
| FI-2, hip flexion, 0–60 | 23.5 (7.0–25.0) | 15.0 (10.0–27.0) |
| HAQ, 0.0–3.0 | 0.63 (0.00–0.13) | 0.25 (0.00–0.88) |
| Patient’s assessment of disease effect on well-being, VAS, 0–10 | 5.0 (1.9–6.9) | 3.2 (1.6–6.5) |
PM: polymyositis; DM: dermatomyositis; JDM: juvenile dermatomyositis; NM: necrotizing myopathy; ASS: antisynthetase syndrome; VAS: visual analog scale; CPK: creatine phosphokinase; MYOACT: Myositis Extra-Muscular Disease Activity Index; MITAX: Myositis Intention to Treat Index; MMT: Manual Muscle Test; FI-2: Functional Index 2; HAQ: Health Assessment Questionnaire.